Atara Biotherapeutics Inc
NASDAQ:ATRA
Relative Value
The Relative Value of one ATRA stock under the Base Case scenario is 14.33 USD. Compared to the current market price of 0.7 USD, Atara Biotherapeutics Inc is Undervalued by 95%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
ATRA Competitors Multiples
Atara Biotherapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
71.3m USD | 15.7 | -0.2 | 0.1 | 0.1 | ||
US |
Abbvie Inc
NYSE:ABBV
|
318.5B USD | 5.9 | 66.1 | 14.2 | 21.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
153.3B USD | 5.4 | 22.8 | 16.8 | 25.2 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 10.9 | 29.7 | 23.9 | 25 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.7B USD | 8.1 | 26.7 | 18.1 | 19.9 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
91B USD | 3.4 | 16.1 | 9.6 | 12.8 | ||
AU |
CSL Ltd
ASX:CSL
|
138.3B AUD | 6.4 | 36.8 | 22.1 | 27.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.2B USD | 6.2 | -9 | -9.5 | -8.1 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 27 | 14.6 | 18.1 | ||
KR |
Celltrion Inc
KRX:068270
|
40.2T KRW | 17.4 | 66.4 | 41.9 | 55 |